Drugs / Autologous Human Schwann Cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05541250 | May 2023 → Sep 2026 overdue | peripheral nerve lesion | W. Dalton Dietrich | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous Human Schwann Cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05541250 ↗ |
| Known as | ahSC | “Autologous Human Schwann Cell (ahSC) Group” NCT05541250 ↗ |
| Modality | Cell therapy | “Participants in this group will undergo a sural nerve biopsy followed by ahSC transplant” NCT05541250 ↗ |